Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer

NCT00093496 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

NIH

Sponsor class

Conditions

Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer

Interventions

DRUG: gemcitabine hydrochloride
DRUG: tanespimycin

Sponsor

National Cancer Institute (NCI)